Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Summary

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Timeline

Start

2022-07-14

Primary completion

2026-06-20

Completion

2026-12

Publications

• Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025 Apr 1;66(4):572-578. doi: 10.2967/jnumed.124.269252.

Drugs

Indications